Amphotericin B - Lypro Biosciences

Drug Profile

Amphotericin B - Lypro Biosciences

Alternative Names: AMB - Lypro Biosciences; AMB-NanoDisk

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator Lypro Biosciences
  • Developer Children's Hospital Oakland Research Institute; Lypro Biosciences
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Aspergillosis; Leishmaniasis

Most Recent Events

  • 01 Aug 2016 Chemical structure information added
  • 26 Jul 2016 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top